Mesirow Financial Investment Management Inc. Has $2.11 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Mesirow Financial Investment Management Inc. lifted its stake in Bristol-Myers Squibb (NYSE:BMY) by 3.8% during the second quarter, Holdings Channel.com reports. The fund owned 50,808 shares of the biopharmaceutical company’s stock after buying an additional 1,882 shares during the period. Mesirow Financial Investment Management Inc.’s holdings in Bristol-Myers Squibb were worth $2,110,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Gryphon Financial Partners LLC grew its stake in shares of Bristol-Myers Squibb by 23.5% in the fourth quarter. Gryphon Financial Partners LLC now owns 5,235 shares of the biopharmaceutical company’s stock valued at $280,000 after buying an additional 995 shares in the last quarter. Gladstone Institutional Advisory LLC grew its position in shares of Bristol-Myers Squibb by 19.8% in the 4th quarter. Gladstone Institutional Advisory LLC now owns 62,786 shares of the biopharmaceutical company’s stock valued at $3,222,000 after acquiring an additional 10,373 shares during the period. Thoroughbred Financial Services LLC increased its stake in shares of Bristol-Myers Squibb by 4.8% during the 4th quarter. Thoroughbred Financial Services LLC now owns 23,095 shares of the biopharmaceutical company’s stock worth $1,185,000 after purchasing an additional 1,065 shares during the last quarter. Clearbridge Investments LLC raised its holdings in shares of Bristol-Myers Squibb by 12.0% in the 4th quarter. Clearbridge Investments LLC now owns 125,980 shares of the biopharmaceutical company’s stock valued at $6,464,000 after purchasing an additional 13,534 shares during the period. Finally, Sachetta LLC acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $57,000. Institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on BMY shares. TD Cowen boosted their price target on Bristol-Myers Squibb from $45.00 to $53.00 and gave the stock a “hold” rating in a research report on Monday, August 12th. StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. Jefferies Financial Group raised their price target on Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a report on Wednesday, August 28th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $50.00 price objective on shares of Bristol-Myers Squibb in a report on Monday. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research report on Tuesday, July 23rd. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $55.00.

Bristol-Myers Squibb Price Performance

Shares of NYSE BMY opened at $50.00 on Tuesday. The business has a fifty day moving average price of $46.99 and a two-hundred day moving average price of $46.47. The stock has a market capitalization of $101.36 billion, a PE ratio of -16.13, a P/E/G ratio of 12.59 and a beta of 0.46. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.16 and a quick ratio of 1.02. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $59.46.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.64 by $0.43. The business had revenue of $12.20 billion during the quarter, compared to the consensus estimate of $11.54 billion. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. Bristol-Myers Squibb’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.75 earnings per share. As a group, equities analysts predict that Bristol-Myers Squibb will post 0.77 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Friday, October 4th will be given a dividend of $0.60 per share. The ex-dividend date is Friday, October 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.80%. Bristol-Myers Squibb’s dividend payout ratio is -77.42%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.